Weissel M, Stanek B, Flygt G
II, Medical University Clinic, Vienna, Austria.
J Cardiovasc Pharmacol. 1990;15 Suppl 4:S95-8. doi: 10.1097/00005344-199015004-00030.
This randomized, double-blind, parallel-group study compared felodipine and hydrochlorothiazide (HCT) given in addition to a beta-blocker in 134 elderly hypertensive patients aged 56-79 years (mean of 66 +/- 5 years). In the felodipine-treated group (n = 57), supine blood pressure (BP) was reduced from 171 +/- 16/101 +/- 6 mm Hg at randomization to 147 +/- 12/86 +/- 6 mm Hg after 8 weeks, whereas in the HCT-treated group (n = 66), BP was reduced from 170 +/- 4/101 +/- 5 to 151 +/- 16/89 +/- 9 mm Hg. The reduction in diastolic blood pressure (DBP) was significantly greater in the felodipine than in the HCT group (p less than 0.003). In the felodipine-treated group, 87% of the patients were controlled (DBP less than or equal to 90 mm Hg) compared with 58% in the HCT group (p less than 0.001). Reported adverse events were generally mild. Six patients withdrew from the study due to adverse events, five in the felodipine group and one in the HCT group.
这项随机、双盲、平行组研究比较了在134名年龄在56至79岁（平均66±5岁）的老年高血压患者中，在使用β受体阻滞剂的基础上加用非洛地平和氢氯噻嗪（HCT）的效果。在非洛地平治疗组（n = 57）中，仰卧位血压（BP）从随机分组时的171±16/101±6 mmHg降至8周后的147±12/86±6 mmHg，而在HCT治疗组（n = 66）中，血压从170±4/101±5降至151±16/89±9 mmHg。非洛地平组的舒张压（DBP）降低幅度显著大于HCT组（p < 0.003）。在非洛地平治疗组中，87%的患者血压得到控制（DBP≤90 mmHg），而HCT组为58%（p < 0.001）。报告的不良事件一般较轻。6名患者因不良事件退出研究，非洛地平组5名，HCT组1名。
